Our findings identify and characterize a new class of compounds that effectively antagonize FOXM1 actions and tumor growth, and may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1. This evidence concerns the gene FOXM1 and neoplasm.